Affiliation:
1. Department of Hematology and Bone Marrow Transplantation, Portuguese Oncology Institute of Porto (IPO-Porto)
Abstract
Abstract
Introduction:
Hepatic sinusoidal obstruction/veno-occlusive syndrome (SOS/VOD) is a major complication following hematopoietic stem cell transplantation, resulting from immune and chemical toxicity to the sinusoidal endothelium and hepatocellular damage. In most severe cases, multiorgan dysfunction occurs, so it is essential to promptly identify patients at greater risk of SOS/VOD and to adopt prophylactic strategies.
Objectives
This study aims to systematize the impact of different approaches as primary prophylaxis of SOS/VOD in patients undergoing hematopoietic progenitors stem cell transplantation (HSCT).
Methods
A systematic review and meta-analysis of randomized clinical trials evaluating different strategies for primary prophylaxis of SOS/VOD was carried out in a pairwise fashion and with a consistent network structure. The odds ratio (OR) and corresponding confidence intervals were calculated using the random-effects model. Heterogeneity was assessed by the I2 method and the efficacy of each approach was estimated by SUCRA (surface under the cumulative ranking curve).
Results
Considering all patients undergoing HSCT, ursodeoxycholic acid (UDCA) [OR = 0.38, 95%CI 0.14–1.06, SUCRA = 0.720] was associated with a lower incidence of VOD while defibrotide reached a modest reduction in its incidence [OR = 0.64, 95%CI 0.23–1.67; SUCRA = 0.486]. Considering the subgroup of patients undergoing hematopoietic progenitors allotransplantation, defibrotide scored higher [OR = 0.51, 95%CI 0.09–2.85, SUCRA = 0.650], by comparison with UDCA [OR = 0.53, 95%CI 0.14–1.96, SUCRA = 0.639].
Conclusion
This is the first meta-analysis comparing primary prophylaxis of SOS/VOD. UDCA yielded more promising results when considering all patients undergoing hematopoietic stem cell transplantation, although, in a subgroup analysis of the ones exposed to allogeneic grafts, it becomes not significantly overrun by defibrotide.
Publisher
Research Square Platform LLC
Reference40 articles.
1. Carreras E, Bertz H, Arcese W, Vernant J-P, Tomás J-F, Hagglund H et al (1998) Incidence and Outcome of Hepatic Veno-Occlusive Disease After Blood or Marrow Transplantation: A Prospective Cohort Study of the European Group for Blood and Marrow Transplantation. Blood [Internet]. ;92(10):3599–604. https://doi.org/10.1182/blood.V92.10.3599
2. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients;Barker CC;Bone Marrow Transplant,2003
3. The role of the endothelium in the short-term complications of hematopoietic SCT;Carreras E;Bone Marrow Transplant,2011
4. Richardson PG, Ho VT, Cutler C, Glotzbecker B, Antin JH, Soiffer R (2013) Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Novel Insights to Pathogenesis, Current Status of Treatment, and Future Directions. Biol Blood Marrow Transplant [Internet]. ;19(1, Supplement):S88–90. Available from: https://www.sciencedirect.com/science/article/pii/S1083879112004521
5. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation;Bonifazi F;Front Immunol,2020